Praxis Precision Medicines, Inc. (PRAX) NASDAQ
258.08
-77.08(-23.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Praxis Precision Medicines, Inc.
Address
99 High Street
Boston, MA 02110
United States of America (the)
Phone
617 300 8460
Sector
Healthcare
Industry
Biotechnology
Employees
116
First IPO Date
October 16, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Marcio Souza | President, Chief Executive Officer & Director | 2.65M | 1979 |
| Alex Nemiroff | General Counsel & Secretary | 1.03M | 1979 |
| Timothy Edwin Kelly | Chief Financial Officer & Treasurer | 1.18M | 1973 |
| Karl Hansen | Chief Technical Operations Officer | 0 | N/A |
| Orrin Devinsky | Head of Clinical Strategy | 0 | 1958 |
| Steven Petrou | Co-Founder and President of Research & Development | 0 | N/A |
| Brian Spar | Chief of Staff | 0 | N/A |
| Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | 0 | 1975 |
| Megan T. Sniecinski | Chief Operating Officer | 0 | 1981 |
| Kelly McCue | Chief People Officer | 0 | N/A |
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
